PHOTO THERA LASER SYSTEM FEASIBILITY ASSESSMENT

PHOTOTHERA INC.,0 个研究点目标入组 0 人开始时间: 2005年9月8日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•1. The Subject is at least 40 years old and under 86 years old.
•2. The Subject suffers from acute ischemic stroke and presents to the community hospital within the first 24 hours of onset.
•3. Possibility of starting treatment with NTS within 24 hours of the start of the ACV.
•4. Clinical diagnosis of ischemic stroke as a cause of measurable neurological deficit.
•5. Total score in the detection of> 7 and <22 on the NIH ACV Scale evaluated at the time of admission to the Community Hospital.
•6. The subject and / or his / her legal representative give their informed consent before taking the study.
•7. The Subject wishes to participate in this study for at least 3 months after the start of the ACV.
•8. It is the opinion of the Principal Investigator, that based on the knowledge of the condition of the subject, as well as the characteristics of the NTS, that the subject is an appropriate candidate for the management of the LCA using an NTS.

•1. The Subject has been presented to the Community hospital more than 24 hours after the start of the ACV.
•2. Evidence of intracranial, subdural, or subarachnoid hemorrhage on CT or MRI.
•3. The subject is a candidate for intravenous administration of tissue plasminogen activator (tPA) for the treatment of acute ischemic stroke and is administered tPA.
•4. The Subject had convulsions at the beginning of the ACV.
•5. Serum glucose greater than 400 mg / dL or less than 40 mg / dL.
•6. Sustained hypertension.
•7. Sustained hypotension.
•8. Presumed septic plunger.
•9. Hereditary or acquired acquired hemorrhagic diathesis.
•10. The subject has an alteration of the skin in the chosen site for the application of infrared energy.

发起方